In summary, we concluded that the interaction of EPN3 with EGFR inhibits the EGFR-targeted lysosomal degradation pathway, promoting EGFR entry into the endocytic recycling system, increasing membrane recycling, increasing EGFR stability, and increasing downstream signalling, all of which contribute to NSCLC progression (Fig. 7). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.